GuidelineCanadian family physician Medecin de famille canadien2018
Simplified guideline for prescribing medical cannabinoids in primary care.
Guideline in Canadian family physician Medecin de famille canadien, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 5 syntheses or guidelines pooled it, 138 citations in OpenAlex.
- Cannabinoid exposure across substance use disorders: Short-term symptom benefits without sustained therapeutic gains in a tier-weighted systematic review.European psychiatry : the journal of the Association of European Psychiatrists · 2026Pooled it
- Medical Cannabis for Chronic Noncancer Pain: A Systematic Review of Health Care Recommendations.Pain research & management · 2021Pooled it
- Efficacy, tolerability and safety of cannabis-based medicines for cancer pain : A systematic review with meta-analysis of randomised controlled trials.Schmerz (Berlin, Germany) · 2019Pooled it
- Managing opioid use disorder in primary care: PEER simplified guideline.Canadian family physician Medecin de famille canadien · 2019Guideline
- Systematic review of systematic reviews for medical cannabinoids: Pain, nausea and vomiting, spasticity, and harms.Canadian family physician Medecin de famille canadien · 2018Pooled it
- Regulation and Use of Cannabidiol in Croatia Compared with Selected European and International Models: From Consumer Products to Clinical Practice.Journal of clinical medicine · 2026Review
- Questioning assumptions about the abuse potential of medical cannabis and cannabinoids: narrative review and commentary.BJPsych bulletin · 2026Review
- Perceptions regarding the use of cannabis in orthopaedics for treating musculoskeletal joint pain: A survey of arthritis patients.The Journal of international medical research · 2026Article
- Pharmacogenetic association study of cannabis use in chronic pain.Journal of cannabis research · 2026Article
- Concomitant use of medical cannabis and drugs associated with risks of interaction in older patients: a longitudinal cohort study.Age and ageing · 2025Article
- Perceptions of cannabis among adults aged 60 years and older in Canada: a qualitative study.Health promotion and chronic disease prevention in Canada : research, policy and practice · 2025Article
- The impact of cannabis use on ageing and longevity: a systematic review of research insights.Journal of cannabis research · 2025Review
- Neuropathic Pain in Cancer: What Are the Current Guidelines?Current treatment options in oncology · 2024Review
- A scoping review of evidence-based guidance and guidelines published by general practice professional organizations.Family practice · 2024Article
- Benzodiazepine use in medical cannabis authorization adult patients from 2013 to 2021: Alberta, Canada.BMC public health · 2024Article
- The Use of Cannabinoids in Pediatric Palliative Care-A Retrospective Single-Center Analysis.Children (Basel, Switzerland) · 2024Article
- Perceptions in orthopedic surgery on the use of cannabis in treating pain: a survey of patients with spine pain (POSIT Spine).Journal of orthopaedic surgery and research · 2024Article
- Planting the seeds for success: A qualitative study exploring primary healthcare providers' perceptions about medical cannabis.PloS one · 2024Article
- Looking Back, Moving Forward in Pain Medicine.Cureus · 2023Review
- Evaluating the Supporting Evidence of Medical Cannabis Claims Made on Clinic Websites: Cross-Sectional Study.Journal of medical Internet research · 2023Article
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 15 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo develop a clinical practice guideline for a simplified approach to medical cannabinoid use in primary care; the focus was on primary care application, with a strong emphasis on best available evidence and a promotion of shared, informed decision making.
methodsThe Evidence Review Group performed a detailed systematic review of 4 clinical areas with the best evidence around cannabinoids: pain, nausea and vomiting, spasticity, and adverse events. Nine health professionals (2 generalist family physicians, 2 pain management-focused family physicians, 1 inner-city family physician, 1 neurologist, 1 oncologist, 1 nurse practitioner, and 1 pharmacist) and a patient representative comprised the Prescribing Guideline Committee (PGC), along with 2 nonvoting members (pharmacist project managers). Member selection was based on profession, practice setting, location, and lack of financial conflicts of interest. The guideline process was iterative through content distribution, evidence review, and telephone and online meetings. The PGC directed the Evidence Review Group to address and provide evidence for additional questions as needed. The key recommendations were derived through consensus of the PGC. The guideline was drafted, refined, and distributed to a group of clinicians and patients for feedback, then refined again and finalized by the PGC. RECOMMENDATIONS: Recommendations include limiting medical cannabinoid use in general, but also outline potential restricted use in a small subset of medical conditions for which there is some evidence (neuropathic pain, palliative and end-of-life pain, chemotherapy-induced nausea and vomiting, and spasticity due to multiple sclerosis or spinal cord injury). Other important considerations regarding prescribing are reviewed in detail, and content is offered to support shared, informed decision making.
conclusionThis simplified medical cannabinoid prescribing guideline provides practical recommendations for the use of medical cannabinoids in primary care. All recommendations are intended to assist with, not dictate, decision making in conjunction with patients.
Indexed as
Identifiers
29449241PMC5964385W2789174467What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.